Alterity Therapeutics (ATHE) Price & Analysis

Compare

292 Followers

ATHE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.00 - $7.00

Previous CloseN/A

Volume131.33K

Average Volume (3M)145.72K

Market Cap

$84.03M

Enterprise Value$2.03M

Total Cash (Recent Filing)$4.54M

Total Debt (Recent Filing)$105.83K

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Feb 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding15,345,777

10 Day Avg. Volume50,393

30 Day Avg. Volume145,723

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.02

Enterprise Value/Revenue0.55

Enterprise Value/Gross Profit0.57

Enterprise Value/Ebitda-0.09

Forecast

1Y Price Target

$8.75

Price Target Upside65.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessPositive news from Phase 2 data in early-stage multiple system atrophy shows ATH434 slowing disease progression and reducing iron accumulation.

Financial PositionAlterity Therapeutics raised substantial funding through a two-tranche financing, potentially providing up to A$40M in additional funding.

Regulatory AdvantageATH434 has orphan drug designation for MSA in both the US and EU.

Bears Say

Stock Price DeclineDespite positive data and demonstration of therapeutic benefit in an extremely challenging setting in advanced MSA, ATHE shares are down ~15% which is attributed to sell-the-news and profit taking.

Alterity Therapeutics News

Alterity Therapeutics reports cash balance of A$40.66M as of June 30

“U.S. FDA Fast Track designation for ATH434 in MSA was the highlight of the recent quarter that also...

15d ago

ATHE

Alterity Therapeutics reports topline data from open-label Phase 2 ATH434 trial

Alterity announced topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with multiple system atrophy....

17d ago

ATHE

Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study

Alterity Therapeutics (ATHE) announced that a neuroimaging measure developed in Alterity’s Biomarkers of Progression in Multiple System Atrophy...

21d ago

ATHE

Buy Rating for Alterity Therapeutics: Promising Phase 2 Results and Investment Opportunity Amid Stock Price Dip

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Alterity Therapeutics, with...

16d ago

ATHE

Alterity Therapeutics Announces Change in Substantial Holding

An update from Alterity Therapeutics ( ($ATHE) ) is now available. On July 7, 2025, Alterity Therapeutics Limited...

1M ago

ATHE

Alterity Therapeutics Announces Cessation of Securities Due to Unmet Conditions

Alterity Therapeutics ( ($ATHE) ) has shared an announcement. On June 30, 2025, Alterity Therapeutics announced the cessation...

1M ago

ATHE

Alterity Therapeutics has several presentations featured at 2025 MSA Congress

Alterity Therapeutics (ATHE) “announced that several oral and poster presentations related to Alterity’s clinical programs in Multiple System...

3M ago

ATHE

Alterity Therapeutics has several presentations featured at 2025 MSA Congress

Alterity Therapeutics (ATHE) “announced that several oral and poster presentations related to Alterity’s clinical programs in Multiple System...

3M ago

ATHE

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

MRK

ATHE

Alterity Therapeutics management to meet with Maxim

Meeting to be held in Boston and New York on May 12-14 hosted by Maxim. Published first on...

3M ago

ATHE

Alterity Therapeutics granted U.S. FDA Fast Track designation for ATH434

Alterity Therapeutics (ATHE) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation for...

3M ago

ATHE

Alterity Therapeutics Reports Positive Phase 2 Trial Results for MSA Treatment

Alterity Therapeutics ( ($ATHE) ) has issued an update. In April 2025, Alterity Therapeutics reported significant progress in...

4M ago

ATHE

Alterity Therapeutics reports cash balance of A$17.96M as of March 31

David Stamler, CEO, commented, “The third fiscal quarter of 2025 was one of our most successful periods to...

4M ago

ATHE

Alterity Therapeutics Announces Director Securities Changes

Alterity Therapeutics ( ($ATHE) ) has issued an announcement. On April 29, 2025, Alterity Therapeutics Limited announced changes...

4M ago

ATHE

ATHE FAQ

What was Alterity Therapeutics Ltd’s price range in the past 12 months?

Alterity Therapeutics Ltd lowest stock price was $1.00 and its highest was $7.00 in the past 12 months.

What is Alterity Therapeutics Ltd’s market cap?

Alterity Therapeutics Ltd’s market cap is $84.03M.

When is Alterity Therapeutics Ltd’s upcoming earnings report date?

Alterity Therapeutics Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 196 days.

How were Alterity Therapeutics Ltd’s earnings last quarter?

Alterity Therapeutics Ltd released its earnings results on Feb 28, 2025. The company reported -$0.435 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.299.

Is Alterity Therapeutics Ltd overvalued?

According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alterity Therapeutics Ltd pay dividends?

Alterity Therapeutics Ltd does not currently pay dividends.

What is Alterity Therapeutics Ltd’s EPS estimate?

Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alterity Therapeutics Ltd have?

Alterity Therapeutics Ltd has 15,345,777 shares outstanding.

What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?

Alterity Therapeutics Ltd reported an EPS of -$0.435 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -2.326%.

Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?

Currently, no hedge funds are holding shares in ATHE

Alterity Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-154.88%

Trailing 12-Months

Asset Growth

-56.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alterity Therapeutics Ltd

Alterity Therapeutics (ATHE) is a biotechnology company focused on developing therapeutic drugs to treat neurodegenerative diseases. The company primarily targets conditions such as Parkinson's disease and other disorders related to the degeneration of the nervous system. Alterity's core products are centered around its proprietary compounds aimed at modulating the biological pathways believed to contribute to these diseases.

Alterity Therapeutics (ATHE) Earnings & Revenues

Historic Earnings Reports

ATHE Stock 12 Month Forecast

Average Price Target

$8.75

▲(65.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","3.5":"$3.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.01,4.624615384615384,5.239230769230769,5.853846153846154,6.468461538461538,7.0830769230769235,7.697692307692308,8.312307692307693,8.926923076923078,9.541538461538462,10.156153846153845,10.77076923076923,11.385384615384616,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.01,4.374615384615384,4.739230769230769,5.1038461538461535,5.468461538461538,5.833076923076923,6.197692307692307,6.562307692307693,6.926923076923076,7.291538461538462,7.656153846153845,8.02076923076923,8.385384615384616,{"y":8.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.01,4.124615384615384,4.239230769230769,4.3538461538461535,4.468461538461538,4.583076923076923,4.697692307692307,4.812307692307693,4.926923076923077,5.041538461538462,5.156153846153846,5.270769230769231,5.385384615384615,{"y":5.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.3,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1654041600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.95,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.31,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >